OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Martin on the Importance of Developing Novel Therapies in MCL

March 11th 2021

Peter Martin, MD, discusses the importance of developing novel therapies in mantle cell lymphoma.

Dr. Basu-Mallick on Selecting Frontline HER2-Directed Therapy in CRC

March 10th 2021

Atrayee Basu-Mallick, MD, discusses factors to consider when selecting a frontline HER2-directed treatment regimen for patients with colorectal cancer.

Dr. Longshore on Key Molecular Markers in Metastatic Lung Cancer

March 10th 2021

John Longshore, PhD, FACMG, discusses key molecular markers in metastatic lung cancer.

Dr. Boyle on the Role of Concurrent Molecular Testing in Lung Cancer

March 10th 2021

Theresa Boyle, MD, PhD, discusses the role of concurrent molecular testing in lung cancer.

Dr. Goy on the Efficacy of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

March 10th 2021

Andre Goy, MD, discusses the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma, as demonstrated in the phase 2 ZUMA-2 trial.

Dr. Pillai on the Importance of Multidisciplinary Discussion in HCC

March 10th 2021

Anjana Pillai, MD, discusses the importance of multidisciplinary discussion in hepatocellular carcinoma.

Dr. Neelapu on Managing Toxicities Associated with CAR T-Cell Products in Lymphoma

March 10th 2021

Sattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.

Dr. Usmani on the Potential Utility of Allogeneic CAR T-Cell Therapy in Multiple Myeloma

March 9th 2021

Saad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.

Dr. Philip on the Emerging Role of ctDNA in CRC

March 9th 2021

Tony Philip, MD, discusses the emerging role of circulating tumor DNA in colorectal cancer.

Dr. Borgen on Treatment Strategies for Male Breast Cancer

March 9th 2021

Patrick Borgen, MD, discusses treatment strategies for patients with male breast cancer.

Dr. Grothey on the Potential Utility of TAS-102/Bevacizumab in Metastatic CRC

March 8th 2021

Axel Grothey, MD, discusses the potential utility of trifluridine/tipiracil in combination with bevacizumab in metastatic colorectal cancer.

Dr. Mead on the Utility of Second-Line Venetoclax/Rituximab in CLL

March 5th 2021

Monica D. Mead, MD, discusses the utility of venetoclax in combination with rituximab in the second-line setting for patients with chronic lymphocytic leukemia.

Dr. Jones on Selecting Between Frontline Regimens in Pancreatic Cancer

March 5th 2021

Amy Jones, MD, discusses factors that can inform frontline treatment selection in pancreatic cancer.

Dr. Martin on the Potential Role of LOXO-305 in MCL

March 5th 2021

Peter Martin, MD, discusses the potential role of LOXO-305 in mantle cell lymphoma.

Dr. Till on the Potential to Utilize CAR T-Cell Therapy Earlier in MCL

March 4th 2021

Brian Till, MD, discusses the potential to utilize CAR T-cell therapy earlier in the treatment of patients with mantle cell lymphoma.

Dr. Bociek on Reserving Allo-SCT for Certain Patients with CLL

March 4th 2021

R. Gregory Bociek, MD, discusses the rationale to reserve allogeneic stem cell transplant for certain patients with chronic lymphocytic leukemia.

Dr. Bekaii-Saab on the Toxicity Differences Between Regorafenib and TAS-102 in CRC

March 4th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer.

Dr. Spira on the Challenges of Developing NRG1 Fusion–Directed Therapies in NSCLC

March 3rd 2021

Alexander Spira, MD, PhD, FACP, discusses the challenges of developing targeted therapies for patients with NRG1 fusion–positive non–small cell lung cancer.

Dr. Grothey on Dosing Strategies With Regorafenib in CRC

March 3rd 2021

Axel Grothey, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC

March 2nd 2021

Alexander Spira, MD, PhD, FACP, discusses the efficacy of mobocertinib in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.